Aurealis Pharma: Development and Tech Transfer of a Live Biotherapeutic Product (LBP)

Aurealis Pharma came to NIZO in 2013 for the development of its proprietary technology, which utilizes genetically modulated lactococcus lactis bacteria that are able to in situ express a variety of therapeutic proteins in the diseased human chronic wound tissue, thus modulating the local immune system and enabling wound healing. These Live Biotherapeutic Products potentially offer sufferers of diabetic ulcers and cancer a much-improved, safer, and more cost-effective treatment option.

NIZO’s expertise in genetic engineering of Lactococcus Lactis using NIZO’s NICE system and its fermentation expertise in lactic acid bacteria helped Aurealis Pharma in the development of its proprietary technology, which utilizes genetically modulated lactococcus lactis bacteria for wound healing. These Live Biotherapeutic Products potentially offer sufferers of diabetic ulcers and cancer a much-improved, safer, and more cost-effective treatment option.

This innovation is explained in more detail on WorldFoodInnovations.com